Table 1.

Respiratory Adverse Event Management Strategies and Outcomes

Adverse Event	Patients who Reported an Adverse Event, n/N (%)	How Often Adverse Events Are Experienced, n/N (%)	Patients who Required Management for Adverse Events, n/N (%)	Management Strategies	Patients who Improved With Management, n/N (%)
Dysphonia	19/26 (73.1)	Sometimes: 5/19 (26.3)Most of the time: 10/19 (52.6)	13/19 (68.4)	Symptomatic: antitussives, lozenges, warm water or glycerin gargle, rinsing mouth after nebulizer use Temporary dosing adjustment: change ALIS administration to the evening or temporarily reduce frequency of ALIS dosing	11/13 (84.6)
Increased sputum	18/26 (69.2)	Sometimes: 8/18 (44.4)Most of the time: 7/18 (38.9)	4/18 (22.2)	Airway clearance: airway clearance/ pulmonary hygiene	3/4 (75.0)
Increased cough	18/26 (69.2)	Sometimes: 8/18 (44.4)Most of the time: 8/18 (44.4)	11/18 (61.1)	Pharmacological: bronchodilator pretreatment Temporary dosing adjustment: temporary reduction in frequency of ALIS dosing or brief interruption of treatment	8/11 (72.7)
Dyspnea	15/26 (57.7)	Sometimes: 5/15 (33.3)Most of the time: 6/15 (40.0)	11/15 (73.3)	Pharmacological: bronchodilator pretreatment Temporary dosing adjustment: temporary reduction in frequency of ALIS dosing or brief interruption of treatment	10/11 (90.9)

Abbreviation: ALIS, amikacin liposome inhalation suspension.